Efficacy and safety of certolizumab pegol therapy for 26 weeks in an unselected Crohn's disease population: Results of the FACTS II survey

Autor:	Janek Binek, Pierre Michetti, Michael Manz, P. De Saussure, Gerhard Rogler, A Schöpfer, Frank Seibold, G Bansky, Martin Geyer, Bernhard Sauter, Stephan R. Vavricka, Alex Straumann, Christian Felley, Michael Scharl
Rok vydání:	2010
Předmět:	medicine.medical_specialty Crohn's disease education.field_of_study business.industry Internal medicine Population Gastroenterology medicine Certolizumab pegol therapy medicine.disease education business
Zdroj:	Zeitschrift für Gastroenterologie. 48
ISSN:	1439-7803 0044-2771
DOI:	10.1055/s-0030-1263685
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2719d9d6c0ac58c9d8c139e47bf9db17 https://doi.org/10.1055/s-0030-1263685 Zobrazit plný text záznamu